




Patología Vascular Periférica

Dr. Claudio Cigalini


Hospital Privado de Rosario

ccigalini@grupogamma.com


Crecimiento de las intervenciones en EVP



5-year Primary Patency (PSVR < 2.0) Zilver PTX vs. Standard Care




At 5 years, Zilver PTX demonstrates a 41% reduction in restenosis compared to standard care




IN.PACT DCB Has Shown Superior Results Compared to PTA in Pivotal IDE Trials


IN.PACT SFA 2-year Patency¹




IN.PACT SFA 3-year Patency²








IN.PACT SFA 4-year FF CD-TLR³





1. Laird J, et al. JACC. 2015;66:2328-2338.
2. Schneider P, et al. Circ Ci. 2018;1-8.
3. Schneider P, VIVA 2017




Herramientas de penetración



Punciones ecoguiadas y accesos distales retrógrados



Available Options




- HawkOne

Directional Atherectomy

- CSI

Orbital Atherectomy




- Laser

Ablative Atherectomy

- JetStream
- Phoenix
- Rotarex

Rotational Atherectomy



Turbohawk™ tecnología

- Capacidad para empacar tejido.
Minimiza el número de inserciones.
- El cortador es radiopaco
Ofrece visualización de embalaje.
- Tecnología MEC (Compresión Micro Eficiente)
Permite un embalaje eficiente




MEC Ventana de
agujeros







SHOCKWAVE




Mechanical Thrombectomy Devices: Penumbra

- CAT6, CAT7, CAT8, CAT12
 - Lightning system – pressure and flow-based algorithms to detect flow v. clot







SUPERA: Freedom From Clinically Driven TLR Through 3 Years




RESILIENT: Freedom from TLR



Kaplan-Meier Survival Analysis; p-value based on a two-sided test with normal approximation




IVUS



More Metal ≠ Better

FIGURE 5 Freedom From CD-TLR for DCB Versus DES (n = 150)




Kaplan Meier Estimates of Event-Free Survival (EFS), Values Represent Patients								
Days Post-Procedure	EFS (%) ± Standard Error		Cumulative Failed (n)		Cumulative Censored (n)		Remaining at risk (n)	
	DCB	DES	DCB	DES	DCB	DES	DCB	DES
0	100 ± 0	100 ± 0	0	0	0	0	75	75
180	100 ± 0	96.0 ± 2.3	0	3	4	5	71	67
365	92.5 ± 3.2	90.0 ± 3.7	5	7	15	13	55	55
730	80.0 ± 5.2	80.1 ± 5.0	12	12	21	21	42	42
1,095	71.3 ± 6.2	68.9 ± 6.2	16	18	27	24	32	33
1,155	71.3 ± 6.2	68.9 ± 6.2	16	18	28	25	31	32

Kaplan-Meier estimates of 6-month, 12-month, 24-month, and 36-month freedom from clinically driven target lesion revascularization (CD-TLR) for DCB (blue curve) and DES (orange curve) with corresponding life tables and patients at risk for both groups. Abbreviations as in Figures 1 to 3.


Revascularización DIRECTA o INDIRECTA

Results

- Direct EVT vs. Indirect EVT -




No. at risk	0	60	120	180	240	300	360
direct EVT	411	325	242	202	172	152	137
indirect EVT	307	200	152	118	101	93	80



- Angiosome-oriented revascularization is widely used in surgical and endovascular treatment (EVT) of patients with critical limb ischemia (CLI), being clinically considered as a reliable strategy for limb salvage

Iida O, et al. J Vasc Surg. 2012;55:363-370
Söderström M, et al. J Vasc Surg. 2013;57:427-35




Equipos Multidisciplinarios

Unidad Vascular Periférica

- Servicios que la componen:
 - Medicina Hospitalaria
 - Clínica Médica
 - Cardiología
 - Diabetes y Metabolismo
 - Cirugía CV
 - Cirugía plástica
 - Traumatología y Ortopedia
 - Cardiología
 - Cardiología Intervencionista
 - Cardioimágenes
 - Diagnóstico por Imágenes
 - Infectología




EVP es común... pero nunca escuché hablar de ella



Gaps in Public Knowledge of Peripheral Arterial Disease: The First National PAD Public Awareness Survey. *Circulation* 2007;116(18):2086-94

EVP es común... pero nunca escuché hablar de ella



¹Multiple Sclerosis: Hope Through Research, NINDS. NIH Publication No. 96-75. September 1996.


²Amyotrophic Lateral Sclerosis Fact Sheet. NINDS. NIH Publication No. 00-916. April 2003.

³Cystic Fibrosis Foundation Fact Sheet, 06/07

⁴Am J Prev Med 2007;32:328-33



Mortalidad relativa a 5 años




* Ankle Brachial Index <0.4

¹ McKenna M et al. *Atherosclerosis*. 1991;87:119-128.

² Ries LAG et al. *SEER Cancer Statistics Review, 1973-1998*. National Cancer Institute. September 2000.

Factores de riesgo CV en EVP



Peripheral artery disease: a global need for detection, prevention, and treatment



I read with interest the study by Min Seo Kim and colleagues¹ on the global burden of peripheral artery disease and its risk factors, based on the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019.

peripheral artery disease burden in 2019 was caused by modifiable risk factors. Unfortunately, there is also poor knowledge and understanding of peripheral artery disease among health-care staff.⁴ In a broader context,

See [Articles](#) page e1553

- Una sustancial proporción de individuos con EVP no son diagnosticados o son insuficientemente tratados
- Propone promover acciones de educación a la comunidad alertando sobre sus riesgos
- Alerta sobre el desconocimiento y pobre entendimiento de la comunidad médica sobre el manejo de la EVP
- La situación empeora en países con bajos ingresos per capita